AstriVax Therapeutics
AstriVax Therapeutics is a clinical stage biopharmaceutical company founded in 2022, focused on developing DNA-based immunotherapies for challenging diseases such as Hepatitis B, Human Papilloma virus, and other emerging viral infectious diseases. They aim to create innovative, single-dose, easy-to-produce vaccines with reduced cold chain requirements, using a patented DNA technology platform that launches self-amplifying live attenuated viral vectors and antigens. The company is engaged in developing vaccines for viral-induced chronic diseases and has a pipeline including therapies for Hepatitis B, HPV, Yellow Fever, and Rabies, with ongoing clinical trials and preclinical research. Their mission is to improve patients' lives through immunotherapies that address chronic diseases, and they emphasize core values of innovation, collaboration, and impact.
Industries
Nr. of Employees
small (1-50)
Products
Therapeutic vaccine candidate for chronic Hepatitis B (DNA-launched viral vector)
Investigational immunotherapy candidate designed to induce virus-specific CD4+ and CD8+ T-cell responses as part of a strategy toward functional cure of chronic hepatitis B.
Investigational therapeutic vaccine candidate for persistent HPV infection
Candidate immunotherapy intended to generate CD8+ T-cell responses to clear persistent high-risk HPV infections and prevent progression to precancerous lesions.
Yellow fever–based viral vector candidate for platform validation
Yellow fever vaccine–based viral vector developed and advanced into Phase I clinical testing to validate platform immunogenicity and scalability using biomarker endpoints.
Yellow fever/rabies-based viral vector candidate for rabies prevention
Viral vector candidate combining yellow fever backbone with rabies antigen sequences, advanced into Phase I testing to assess safety and immune response for rabies prevention.
Therapeutic vaccine candidate for chronic Hepatitis B (DNA-launched viral vector)
Investigational immunotherapy candidate designed to induce virus-specific CD4+ and CD8+ T-cell responses as part of a strategy toward functional cure of chronic hepatitis B.
Investigational therapeutic vaccine candidate for persistent HPV infection
Candidate immunotherapy intended to generate CD8+ T-cell responses to clear persistent high-risk HPV infections and prevent progression to precancerous lesions.
Yellow fever–based viral vector candidate for platform validation
Yellow fever vaccine–based viral vector developed and advanced into Phase I clinical testing to validate platform immunogenicity and scalability using biomarker endpoints.
Yellow fever/rabies-based viral vector candidate for rabies prevention
Viral vector candidate combining yellow fever backbone with rabies antigen sequences, advanced into Phase I testing to assess safety and immune response for rabies prevention.
Services
Collaborative clinical validation through global health programs
Partners with global health initiatives to run clinical validation studies using platform-derived viral vectors, with a focus on correlates of protection and scalability.
Platform licensing and partnership for vaccine development
Collaborative development and licensing opportunities for the plasmid-launched viral vector platform to develop prophylactic and therapeutic vaccines.
Collaborative clinical validation through global health programs
Partners with global health initiatives to run clinical validation studies using platform-derived viral vectors, with a focus on correlates of protection and scalability.
Platform licensing and partnership for vaccine development
Collaborative development and licensing opportunities for the plasmid-launched viral vector platform to develop prophylactic and therapeutic vaccines.
Expertise Areas
- Vaccine platform development
- Plasmid-based viral vector engineering
- Immunotherapy for chronic viral infections
- Preclinical and translational research (cell culture and animal models)
Key Technologies
- Plasmid-launched self-amplifying live attenuated viral vectors
- Two-step plasmid DNA manufacturing
- Live-attenuated yellow fever vaccine backbone vectors
- Thermostable vaccine formulations